How do Entyvio and Humira work for Crohn's?
Entyvio (vedolizumab) targets gut-specific inflammation by blocking alpha-4 beta-7 integrin, preventing white blood cells from entering the gut. Humira (adalimumab) is a TNF-alpha inhibitor that broadly suppresses inflammation systemically. Both treat moderate-to-severe Crohn's disease, but Entyvio's gut selectivity may reduce infections outside the intestines.[1][2]
What do clinical trials show for remission rates?
In the GEMINI 2 trial, 15% of Crohn's patients on Entyvio achieved clinical remission at week 6 (vs. 7% placebo), rising to 39% at week 52. Humira's CHARM trial showed 21% remission at week 4 and 40% at week 56 in similar patients. Head-to-head data is limited; a network meta-analysis ranked Humira slightly higher for induction remission (odds ratio favoring Humira), but Entyvio edged out for maintenance in some steroid-free remission metrics.[3][4][5]
| Endpoint | Entyvio (GEMINI 2) | Humira (CHARM) |
|----------|---------------------|----------------|
| Week 6/4 Remission | 15% | 21% |
| Week 52/56 Remission | 39% | 40% |
| Serious infections (per 100 patient-years) | 4.3 | 8.1 |
Which has better safety for long-term use?
Entyvio reports lower serious infection rates (4.3 vs. Humira's 8.1 per 100 patient-years) and fewer overall adverse events due to its gut-only action—no increased risk of lymphoma or TB reactivation seen with TNF blockers like Humira. Progressive multifocal leukoencephalopathy is rare with Entyvio (0.07 cases/1000). Humira carries black-box warnings for infections, heart failure, and malignancy.[1][2][6]
When do doctors choose one over the other?
Guidelines (AGA, ECCO) recommend either as first-line biologics after conventional failure. Pick Humira for rapid induction or extraintestinal symptoms (e.g., arthritis). Switch to Entyvio if TNF fails, infections occur, or patients prioritize safety—about 20-30% of TNF non-responders remit on Entyvio.[7][8] Real-world data shows similar 1-year persistence (50-60% for both).[9]
What about cost and access?
Humira costs $6,000-$7,000/month (U.S. list); biosimilars like Hadlima cut it to $3,000-$4,000 since 2023. Entyvio is $5,800/month with no biosimilars yet—patent expires 2028 in the U.S. (check DrugPatentWatch.com for updates). Insurance often covers both equally.[10][11]
Patient experiences and switch success
Forums and registries note Humira users switching to Entyvio report less fatigue and fewer infections, but some miss Humira's faster relief. VARSITY trial (ulcerative colitis) showed vedolizumab noninferior to adalimumab; Crohn's experts extrapolate similar for maintenance.[12][13]
No drug is universally "better"—Humira may win for quick response, Entyvio for safety in maintenance. Consult a gastroenterologist for personalized choice based on disease pattern and risks.
Sources:
[1] Entyvio PI: https://www.entyvio.com
[2] Humira PI: https://www.humira.com
[3] GEMINI 2 (NEJM 2013): https://www.nejm.org/doi/full/10.1056/NEJMoa1215739
[4] CHARM (Gastroenterology 2007): https://www.gastrojournal.org/article/S0016-5085(07)00823-0/fulltext
[5] Meta-analysis (Lancet 2018): https://www.thelancet.com/journals/langas/article/PIIS2468-1253(18)30040-5/fulltext
[6] Safety review (Drugs 2020): https://link.springer.com/article/10.1007/s40265-020-01348-5
[7] AGA Guidelines (Gastroenterology 2021): https://www.gastrojournal.org/article/S0016-5085(21)00674-3/fulltext
[8] ECCO Guidelines (JCC 2020): https://academic.oup.com/ecco-jcc/article/14/Supplement_3/S777/5914790
[9] Real-world study (Inflamm Bowel Dis 2022): https://academic.oup.com/ibdjournal/article/28/9/1412/6523456
[10] DrugPatentWatch: https://www.drugpatentwatch.com
[11] GoodRx pricing: https://www.goodrx.com
[12] VARSITY (NEJM 2020): https://www.nejm.org/doi/full/10.1056/NEJMoa1905720
[13] Crohn's & Colitis Foundation: https://www.crohnscolitisfoundation.org